POLYMYALGIA RHEUMATICA AND GIANT CELL ARTERITIS UK

Active

Registry details

Reference data exactly as held at Companies House.

Copy registry details
Registered office
15 Stoneleigh Avenue, Brighton BN1 8NP
Accounts type
Micro Entity

Company activity

The 4 most recent documents filed at Companies House.

Pre-Score for UK companies is coming soon
  1. 02/06/2026

    Appointment of Mrs Stephanie Anne Beer as a director on 2026-06-01

    View PDF (2 pages)
  2. 26/02/2026

    Appointment of Miss Janette Elizabeth Mannell as a secretary on 2026-02-23

    View PDF (2 pages)
  3. 12/01/2026

    Confirmation statement made on 2025-12-02 with no updates

    View PDF (3 pages)
  4. 12/01/2026

    Registered office address changed from 10 Coldbath Square London EC1R 5HL to 15 Stoneleigh Avenue Brighton BN1 8NP on 2026-01-12

    View PDF (1 pages)

Accounts and confirmation statement

The two filings Companies House requires every year, and where each one stands against its deadline today.

Annual accounts

Micro Entity accounts

Due in 89 days

31/12/2026Filing deadline

Next accounts made up to
31/03/2026
Last accounts made up to
31/03/2025

Confirmation statement

Confirms the registry record is up to date

Due in 74 days

16/12/2026Filing deadline

Next statement date
02/12/2026
Last statement dated
02/12/2025

See the full filing history

Financial performance

The latest figures POLYMYALGIA RHEUMATICA AND GIANT CELL ARTERITIS UK filed. Okredo holds filed accounts data for 2021–2025; the year-by-year record is on the financials page.

Net Assets

£222.25K2025
3.07%vs 2024

2024: £215.63K

Total Assets

£224.15K2025
2.22%vs 2024

2024: £219.27K

Total Liabilities

£1.90K2025
-47.85%vs 2024

2024: £3.65K

Employees

32025
0vs 2024

2024: 3

Of the 3 measures with an earlier filing to compare against, 2 rose and 1 fell. Net assets moved furthest, up 3.07% on 2024. See the full financial analysis for POLYMYALGIA RHEUMATICA AND GIANT CELL ARTERITIS UK.

Employees

Headcount as reported to Companies House for 2021–2025.

22021
32022
52023
32024
32025
YearEmployeesChange
202530
20243-2
20235+2
20223+1
20212–

Reported employee count increased from 2 in 2021 to 3 in 2025. See how headcount moved alongside the reported financials.

Credit report

It is a professional assessment of the company 's performance, revealing company's potential and risks, showing it's past experiences and revealing future prospects.

Officers

36

Directors, secretaries and other appointed officers, with the period each has served.

PersonRolePeriodConnected companies
Director06/12/2023–Present0
Director13/06/2018–30/07/202011
Director30/11/2015–07/07/20227
Director02/12/2008–10/06/20110
Director07/10/2009–23/04/20100
Director02/12/2008–10/06/20110
Director02/12/2008–22/10/20091
Director08/06/2013–30/11/20150
Director07/10/2009–31/12/20130
Director08/09/2018–13/02/20240
Director02/12/2008–06/09/20250
Director07/10/2009–28/02/20100
Director01/02/2017–Present1
Director30/11/2015–11/04/20180
Director09/06/2011–06/06/20130
Director30/11/2015–09/09/20230
Director02/12/2008–10/06/20110
Director29/06/2022–Present0
Director21/06/2023–Present0
Director11/04/2018–06/09/20256
Director30/11/2015–09/09/202310
Director06/12/2023–Present1
Director01/06/2026–Present2
Director30/09/2020–Present89
Director09/06/2011–07/02/20180
Director23/04/2010–15/06/20160
Director04/02/2020–08/02/20222
Director02/12/2008–30/06/20100
Director09/06/2011–30/11/20152
Director02/12/2008–10/06/20111
Director08/06/2013–18/06/20150
Director30/11/2015–31/03/20171
Director11/09/2012–18/06/20150
Director06/09/2025–Present2
Director15/05/2026–Present0
Secretary23/02/2026–Present0

Persons with significant control

1

Individuals or entities with significant control over the company, as declared to Companies House.

PersonPeriodConnected companies
02/12/2016–Present0

Filing history and recent activity

Every document on the Companies House record, newest first.

Filings on record
24
Since 14/10/2022
Last 12 months
5
-1 vs the year before
Most recent filing
02/06/2026
4 months ago

What changed in the last year

  • Officer changes (2)Latest 02/06/2026
  • Confirmation statementLatest 12/01/2026
  • Registered officeLatest 12/01/2026
  • Accounts filedLatest 04/12/2025

Filing timeline

  1. 02/06/2026

    Appointment of Mrs Stephanie Anne Beer as a director on 2026-06-01

    View PDF (2 pages)
  2. 26/02/2026

    Appointment of Miss Janette Elizabeth Mannell as a secretary on 2026-02-23

    View PDF (2 pages)
  3. 12/01/2026

    Confirmation statement made on 2025-12-02 with no updates

    View PDF (3 pages)
  4. 12/01/2026

    Registered office address changed from 10 Coldbath Square London EC1R 5HL to 15 Stoneleigh Avenue Brighton BN1 8NP on 2026-01-12

    View PDF (1 pages)
  5. 04/12/2025

    Micro company accounts made up to 2025-03-31

    View PDF (3 pages)
  6. 10/09/2025

    Appointment of Ms Margaret Fiona Bassendine as a director on 2025-09-06

    View PDF (2 pages)
  7. 09/09/2025

    Termination of appointment of Humphrey Julian Francis Hodgson as a director on 2025-09-06

    View PDF (1 pages)
  8. 09/09/2025

    Termination of appointment of Wendy Jane Morrison as a director on 2025-09-06

    View PDF (1 pages)
  9. 11/12/2024

    Termination of appointment of Sara Nicole Muller as a director on 2024-02-13

    View PDF (1 pages)
  10. 11/12/2024

    Confirmation statement made on 2024-12-02 with no updates

    View PDF (3 pages)
  11. 24/10/2024

    Micro company accounts made up to 2024-03-31

    View PDF (3 pages)
  12. 15/12/2023

    Register inspection address has been changed from 56 Manor Road London N16 5BN England to 21 Minety Road Swindon Wiltshire SN2 5PQ

    View PDF (1 pages)

Showing 12 of 24 filings

See when the next accounts and confirmation statement are due

Similar companies

1,541 UK companies are similar to POLYMYALGIA RHEUMATICA AND GIANT CELL ARTERITIS UK, sharing the same company status (Active), the same industry sector and activity group (Other service activities n.e.c. goods- and services-producing activities of households for own use) and a comparable number of employees. The 5 closest matches are shown below to help you compare competitors and industry peers.

1,541 UK companies share this business profileThe 5 above are the closest matches. See every UK company registered under Other service activities n.e.c. goods- and services-producing activities of households for own use.Browse the listing

About POLYMYALGIA RHEUMATICA AND GIANT CELL ARTERITIS UK

A short description of the company, written from its Companies House record.

POLYMYALGIA RHEUMATICA AND GIANT CELL ARTERITIS UK is a private limited company by guarantee without share capital, use of "limited" exemption registered in the United Kingdom, based in 15 Stoneleigh Avenue, Brighton BN1 8NP. Companies House classifies its business as Other service activities n.e.c. goods- and services-producing activities of households for own use. It has been on the register for 17 years 10 months.

The register currently records it as active. Its 2025 accounts report net assets of £222.25K and 3 employees.

POLYMYALGIA RHEUMATICA AND GIANT CELL ARTERITIS UK: frequently asked questions

Answered from this company's own registry record and filed figures.

Companies House records POLYMYALGIA RHEUMATICA AND GIANT CELL ARTERITIS UK under one registered business activity: Other service activities n.e.c. goods- and services-producing activities of households for own use (96.09 - SIC 2007).

POLYMYALGIA RHEUMATICA AND GIANT CELL ARTERITIS UK is recorded as active on the Companies House register, and has been on it since 02/12/2008.

The most recent accounts Okredo holds cover 2025 and report net assets of £222.25K, total assets of £224.15K and total liabilities of £1.90K.

The most recent document on the record is dated 02/06/2026: Appointment of Mrs Stephanie Anne Beer as a director on 2026-06-01, 4 months ago.

On the current registry record, accounts are due by 31/12/2026 and the next confirmation statement is due by 16/12/2026.

Companies House lists 36 officers (10 currently in post) and 1 person with significant control.